Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma

Sözen, Hamdullah; Çiftçi, Rümeysa; Vatansever, Doğan; Topuz, Samet; İyibozkurt, Ahmet Cem; Bozbey, Hamza Ugur; Yaşa, Cenk; Çalı, Halime; Yavuz, Ekrem; Küçücük, Seden; Aydıner, Adnan; Salihoğlu, Yavuz

doi:10.1111/ajo.12449

Cited by 7 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, tumor recurrence was significantly associated with increased serum levels of CA-125, increased histologic grade, and the presence of LVSI. Sozen et al studied the relevant risk factors associated with survival and relapse rates in patients with early-stage endometrial cancer and showed that age >50 years, histological subtype, and treatment with adjuvant radiotherapy had a significant impact on tumor recurrence [12]. The data presented in the present study showed that increased serum CA-125 levels and increased histologic grade were independent predictors for disease-free survival (DFS).…”

Section: Discussionmentioning

confidence: 49%

The Effect of Prognostic Factors and Adjuvant Radiotherapy on Survival in Patients with High-Grade Early-Stage Endometrial Cancer: A Retrospective Clinical Study

et al. 2019

View full text Add to dashboard Cite

Background This retrospective clinical study aimed to investigate the effect of prognostic factors and adjuvant radiotherapy in patients with high-grade early-stage endometrial cancer on overall survival (OS) and disease-free survival (DFS). Material/Methods The medical records of patients diagnosed with high-grade, early stage (I or II) endometrial adenocarcinoma who had received adjuvant radiotherapy after surgery were reviewed. Results Seventy-nine patients included 39 patients (49.4%) with stage II endometrial cancer, 25 patients (31.6%) with histologic grade 3 tumors, and 47 patients (59.5%) with endometrial cancer showing lymphovascular space invasion (LVSI). There were 45 patients (57.0%) who received external pelvic radiotherapy with an average dose of 46.0 Gy (range, 11.2–50.4 Gy), and 34 patients (43.0%) received vaginal brachytherapy (VBT) with an average dose of 21.5 Gy (range, 10–36 Gy). Multivariate analysis showed that tumor stage (HR, 4.066; 95% CI, 1.227–13.467; p=0.022) and histologic grade (HR, 16.652; 95% CI, 4.430–62.589; p<0.001) were independent predictors for OS. Increased serum CA-125 levels (HR, 1.136; 95% CI, 0.995–1.653; p=0.047) and histologic grade (HR, 3.236; 95% CI, 1.107–15.156; p=0.015) were independent predictors for DFS. Adjuvant radiotherapy was not found to be significantly associated with improved OS (HR, 1.259; 95% CI, 0.518–3.058; p=0.612) or DFS (HR, 1.056; 95% CI, 0.994–1.123; p=0.078). Conclusions This retrospective study showed that in high-grade early-stage endometrial cancer treated with postoperative adjuvant radiotherapy, independent predictors for OS were tumor stage and grade. Adjuvant radiotherapy was not associated with improved OS or DFS.

show abstract

Section: Discussionmentioning

confidence: 49%

The Effect of Prognostic Factors and Adjuvant Radiotherapy on Survival in Patients with High-Grade Early-Stage Endometrial Cancer: A Retrospective Clinical Study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A benefit to combining adjuvant CTand RTwas observed in a retrospective series from Turkey that evaluated stages I and II EC, including 23 stage II patients. 17 In a retrospective series from Japan, which included 16 patients with stage II disease who did not receive RT, adjuvant CT was associated with improved OS in patients with grade 3 disease and LVI. 12 A retrospective series from Italy of stage Ib or II with myometrial invasion greater than 50%, grades 2 and 3 tumors, found that adjuvant CT with RT was associated with a trend toward improved OS.…”

Section: Subgroupsmentioning

confidence: 99%

Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer

Lester-Coll

Young²,

Park³

et al. 2017

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…But external exposure and internal irradiation are both mainly effective to G2/M phase cells and neither of them has effect on S and G0 phase cells and hypoxic cells, which commonly results in radioresistance. Encouragingly, combination of two methods or more is often superior to any single scheme 6 7 8 9 10 . It is reported that both short-term and long-term (survival rate of six months, one year and two years) curative effects (CR + PR) of radiotherapy combined with chemotherapeutics against cervical cancer, lung cancer, and esophageal squamous cell carcinoma and nasopharyngeal carcinoma are significantly better than those of any regime alone 11 12 13 14 15 .…”

mentioning

confidence: 99%

A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH

Lin

Huang

Jiang

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Combination targeted therapy is a promising cancer therapeutic strategy. Here, using PEI-Mn0.5Zn0.5Fe2O4 nanoparticles (PEI-MZF-NPs) as magnetic media for MFH (magnetic fluid hyperthermia) and gene transfer vector for gene-therapy, a combined therapy, pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH, for hepatoma is developed. AntiAFPMcAb (Monoclonal antibody AFP) is exploited for targeting. The plasmids pHRE-Egr1-HSV-TK are achieved by incorporation of pEgr1-HSV-TK and pHRE-Egr1-EGFP. Restriction enzyme digestion and PCR confirm the recombinant plasmids pHRE-Egr1-HSV-TK are successfully constructed. After exposure to the magnetic field, PEI-MZF-NPs/pHRE-Egr1-EGFP fluid is warmed rapidly and then the temperature is maintained at 43 °C or so, which is quite appropriate for cancer treatment. The gene expression reaches the peak when treated with 200 μCi 131I for 24 hours, indicating that the dose of 200 μCi might be the optimal dose for irradiation and 24 h irradiation later is the best time to initiate MFH. The in vitro and in vivo experiments demonstrate that pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH can greatly suppress hepatic tumor cell proliferation and induce cell apoptosis and necrosis and effectively inhibit the tumor growth, much better than any monotherapy does alone. Furthermore, the combination therapy has few or no adverse effects. It might be applicable as a strategy to treat hepatic cancer.

show abstract

Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma

Abstract: We identified that a combination treatment of chemotherapy and radiotherapy is superior compared to other postoperative adjuvant treatment approaches concerning PFS, OS and recurrence rates in stages I-II of type II endometrial cancers and uterine carcinosarcoma.

Cited by 7 publications

References 29 publications

The Effect of Prognostic Factors and Adjuvant Radiotherapy on Survival in Patients with High-Grade Early-Stage Endometrial Cancer: A Retrospective Clinical Study

The Effect of Prognostic Factors and Adjuvant Radiotherapy on Survival in Patients with High-Grade Early-Stage Endometrial Cancer: A Retrospective Clinical Study

Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer

A combination hepatoma-targeted therapy based on nanotechnology: pHRE-Egr1-HSV-TK/131I-antiAFPMcAb-GCV/MFH

Contact Info

Product

Resources

About